|
Dec 8
|
FDA approves gene-editing therapy for sickle cell disease
|
|
Dec 8
|
FDA Approves First Two Sickle Cell Gene Therapies, bluebird bio Shares Tumble
|
|
Dec 8
|
FDA Approves World’s First Crispr Gene-Editing Drug for Sickle-Cell Disease
|
|
Dec 8
|
Vertex and CRISPR Therapeutics Announce US FDA Approval of CASGEVY™ (exagamglogene autotemcel) for the Treatment of Sickle Cell Disease
|
|
Dec 8
|
Shares of Crispr Therapeutics Swing After FDA's OK. Is the Stock Safe?
|
|
Dec 8
|
CRISPR Therapeutics Just Slashed Its Staff by 10%. Should Shareholders Be Worried?
|
|
Dec 8
|
CRISPR therapy for sickle cell approved by FDA in gene editing milestone
|
|
Dec 7
|
Play US Gene Treatment Approval in SBIO
|
|
Dec 7
|
This Newly Discovered Risk Could Be a Big Headache for Vertex Pharmaceuticals and CRISPR Therapeutics
|
|
Dec 7
|
5 Unstoppable Trends to Invest $1,000 in for 2024
|
|
Dec 6
|
Is This News a Setback or a Step Forward for CRISPR Therapeutics?
|
|
Dec 6
|
CRISPR Therapeutics AG (CRSP) Up 20.5% Since Last Earnings Report: Can It Continue?
|
|
Dec 6
|
Wall Street Analysts Think CRISPR Therapeutics AG (CRSP) Could Surge 27.15%: Read This Before Placing a Bet
|
|
Dec 6
|
Wager on WDNA for Biotech Rebound
|
|
Dec 5
|
CRISPR (CRSP) to Focus on Next-Generation CAR T Pipeline
|
|
Dec 5
|
1 Promising Stock Down 66% That Could Skyrocket in 2024
|
|
Dec 5
|
Better Growth Stock: CRISPR Therapeutics vs. Invitae
|
|
Dec 5
|
CRISPR eyes autoimmune disease in revamp of cell therapy plans
|
|
Dec 5
|
The Market's Up This Year. Do You Feel Like You Are Winning?
|
|
Dec 4
|
CRISPR Therapeutics Announces Updates to Immuno-Oncology Pipeline and Expansion into Autoimmune Disease
|